Atty. Docket: 60711.000023 IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

re Patent Application of:)
J. ESCARY)
Serial No.: 10/673,886) Art Unit: Unassigned
Filed: September 30, 2003) Examiner: Unassigned

For: NEW POLYNUCLEOTIDES AND POLYPEPTIDES OF THE IFNα-21 GENE

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. §§ 1.56, 1.97, and 1.98, Applicants respectfully request consideration of the references listed on the attached Form PTO/SB/08A. Copies of the references listed are also enclosed.

Applicants respectfully point out that the submission of the listed documents in this Information Disclosure Statement is not an admission that they are prior art or that they are material to patentability of any claims of the application. Also, the submission of this Information Disclosure Statement is not an indication that a search has been made.

Applicants respectfully request that the Examiner consider the references cited on the Form PTO/SB/08A and that the Examiner indicate that the references have been considered in this application by returning a copy of the Form PTO/SB/08A with the Examiner's initials in the left column per MPEP 609.

PATENT Atty. Docket: 60711.000023

This IDS is submitted prior to the issuance of a first Office Action on the merits; therefore, it is believed that no fees are required in connection therewith. If any fees are necessitated by the filing of this Information Disclosure Statement, please charge the undersigned's Deposit Account No. 50-0206.

Respectfully submitted,

HUNTON & WILLIAMS LLP

Date: <u>Jan. 13</u>, 2004

Registration No. 42, 202

1900 K Street, N.W., Suite 1200 Washington, D.C. 20006-1109 Ph. (202) 955-1500 Fax (202) 778-2201 SV/sdw

PTO/SB/08A (10/01) (modified)

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE Substitute for form 1449A/PTO **Application Number** 10/673,886 Filing Date **September 30, 2003** INFORMATION DISCLOSURE **First Named Inventor** J. ESCARY STATEMENT BY APPLICANT Art Unit Unassigned (use as many sheets as necessary) **Examiner Name** Unassigned of 2 **Sheet** 1 **Attorney Docket Number** 60711.000023 **U.S. PATENT DOCUMENTS** Pages, Columns, Lines, DOCUMENT NUMBER **Publication Date** Name of Patentee or Where Relevant Passages or Initials No. MM-DD-YYYY Number - Kind Code (if known) Applicant of Cited Document Relevant Figures Appear US-4801685 1. 01-31-1989 Goeddel et al. **FOREIGN PATENT DOCUMENTS FOREIGN PATENT** DOCUMENT Name of Patentee or Pages, Columns, Lines, TRANSLATION Number - Kind Code Country *Examiner Cite **Publication Date** Applicant of Cited Where Relevant Passages (if known) Code: Initial No. MM-DD-YYYY Document or Relevant Figures Appear YES NO WO 84/00776 03-01-1984 \boxtimes 2. Innis 3. EP 0 173 887 B1 07-29-1987 Teraoka et al. \boxtimes Ø GB 2 079 291 A 01-20-1982 Goeddel et al. П 4. Heinrichs et al. 5. WO 01/25438 A2 04-04-2001 \boxtimes WO 00/39280 Morris et al. \boxtimes 6. 07-06-2000 NON-PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the *Examine item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue Initials No. number(s), publisher, city and/or country where published NCBI Sequence Viewer, Homo sapiens interferon, alpha 21 (IFNA21), mRNA, ABSTRACT, 4 7. pages NCBI Sequence Viewer, Homo sapiens clone RP11-1P8, Working Draft Sequence, 15 8 unordered pieces, 1 page, ABSTRACT VELAN, B. et al, Interferon Alpha-A Precursor, Medline, XP-002187983, ABSTRACT, 1 page 9. **EXAMINER SIGNATURE** DATE CONSIDERED *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ه د سره

JAN 1 3 2004

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of

2

Sheet

2

	Application Number	10/673,886	
l	Filing Date	September 30, 2003	
Ì	First Named Inventor	J. ESCARY	
	Art Unit	Unassigned	
	Examiner Name	Unassigned	
-	Attorney Docket Number	60711.000023	
	<u> </u>		

NON-PATENT LITERATURE DOCUMENTS

NON I ATEN				
*Examiner	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published		
	10.	DAVID V. GOEDDEL et al., "The structure of eight distinct cloned human leukocyte interferon cDNAs," Nature Vol. 290, March 5, 1981, pp. 20-26		
	11.	AXEL ULLRICH et al., "Nucleotide Sequence of a Portion of Human Chromosome 9 Containing a Leukocyte Interferon Gene Cluster," J. Mol. Biol. (1982) 156, pp. 467-486		
	12.	H. WEBER et al., "Single amino acid changes that render human IFN-α2 biologically active on mouse cells," The EMBO Journal, Vol. 6, No. 3, pp. 591-598, 1987		
	13.	ANN-CHRISTINE SYVÄNEN et al., "Identification of Individuals by Analysis of Biallelic DNA Markers, Ising PCR and Solid-Phase Minisequencing," Am. J. Genet., Vol. 52, pp. 46-59, 1993		
	14.	MUSADDEQ HUSSAIN et al., "Identification of Interferon-α7, -α14, and -α21 Variants in the Genome of a Large Human Population," Journal of Interferon And Cytokine Research, Vol. 16, pp. 853-859, (1996)		
	15.	ROB L. H. JANSEN et al., "Interleukin-2 and Interferon-α in the Treatment of Patients with Advanced Non-Small-Cell Lung Cancer," Journal Of Immunotherapy, Vol. 12, No. 1, 1992, pp. 70-73		
	16.	EIJI MITA et al., "Predicting Interferon Therapy Efficacy from Hepatitis C Virus Genotype and RNA Titer," Digestive Diseases and Science, Vol. 39, No. 5, (May 1994), pp. 977-982		
	17.	RYO YAMADA et al., "Identification of 142 single nucleotide polymorphisms in 41 candidate genes for rheumatoid arthritis in the Japanese population," Hum. Genet. (2000), Vol. 106, pp. 293-297		
	18.	O. I. OLOPADE et al., "Mapping of the Shortest Region of Overlap of Deletions of the Shortest Region of Overlap of Deletions of the Shortest Remains of Chromosome 9 Associated with Human Neoplasia," Genomics 14, pp. 437-443 (1992) International Search Report dated 6/13/03 for Application No. PCT/EP02/04082		
	19.			

EXAMINER SIGNATURE

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.